Announcement • May 29
Sequana Medical Presents Data on Recompensation of Decompensated Cirrhosis Following Alfapump Placement At EASL Congress 2026 Sequana Medical NV announced the presentation of data from a post-hoc analysis of the Phase 3 POSEIDON study of alfapump at the European Association for the Study of the Liver (EASL) Cong ress 2026 in Barcelona, Spain. EASL Congress is one of the world’s premier events dedicated to liver health, bringing together physicians, scientists, and allied health professionals from across the globe to share knowledge and highlight breakthroughs across the full spectrum of hepatology. The poster, titled “Recompensation of decompensated cirrhosis and long-term resolution of ascites in patients undergoing alfapump placement: experience from the multi-centre POSEIDON study,” was presented in the Portal Hypertension session. The alfapump is a subcutaneous implantable device that automatically and continuously moves ascites fluid from the abdominal cavity into the bladder, where it is eliminated naturally, freeing patients from dependence on repeated large-volume paracentesis procedures. Of 48 subjects with a functioning alfapump at six months post-implant, 10 achieved recompensation, with a median time to recompensation of 519 days. Key markers of recovery, including declining MELD-Na (Model for End-Stage Liver Disease-Sodium, a standard measure of liver disease severity) scores and rising serum albumin, differentiated those who recompensated from those who did not. Both the Recompensation group (n = 10) and those with Ongoing Decompensation (n = 38) experienced similar post-implant improvements in ascites complaints (Ascites-Q). These findings are preliminary and further data collection is ongoing. The alfapump system received U.S. FDA Premarket Approval in December 2024 for the treatment of recurrent or refractory ascites due to liver cirrhosis. It is the first and currently only U.S.-approved active implantable medical device (Class III) that automatically and continuously removes ascites from the abdomen into the bladder. In August 2025, CMS approved the New Technology Add-on Payment for the alfapump when performed in the hospital inpatient setting, effective October 1, 2025. Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. Observer Erik Amble was the last director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. 
